436 related articles for article (PubMed ID: 23774435)
1. In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi.
Soeiro Mde N; de Souza EM; da Silva CF; Batista Dda G; Batista MM; Pavão BP; Araújo JS; Aiub CA; da Silva PB; Lionel J; Britto C; Kim K; Sulikowski G; Hargrove TY; Waterman MR; Lepesheva GI
Antimicrob Agents Chemother; 2013 Sep; 57(9):4151-63. PubMed ID: 23774435
[TBL] [Abstract][Full Text] [Related]
2. Antitrypanosomal Activity of Sterol 14α-Demethylase (CYP51) Inhibitors VNI and VFV in the Swiss Mouse Models of Chagas Disease Induced by the Trypanosoma cruzi Y Strain.
Guedes-da-Silva FH; Batista DG; Da Silva CF; De Araújo JS; Pavão BP; Simões-Silva MR; Batista MM; Demarque KC; Moreira OC; Britto C; Lepesheva GI; Soeiro MN
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167559
[TBL] [Abstract][Full Text] [Related]
3. Successful Aspects of the Coadministration of Sterol 14α-Demethylase Inhibitor VFV and Benznidazole in Experimental Mouse Models of Chagas Disease Caused by the Drug-Resistant Strain of Trypanosoma cruzi.
Guedes-da-Silva FH; Batista DDGJ; Da Silva CF; Pavão BP; Batista MM; Moreira OC; Souza LRQ; Britto C; Rachakonda G; Villalta F; Lepesheva GI; Soeiro MNC
ACS Infect Dis; 2019 Mar; 5(3):365-371. PubMed ID: 30625275
[TBL] [Abstract][Full Text] [Related]
4. Complexes of Trypanosoma cruzi sterol 14α-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen selectivity.
Hargrove TY; Wawrzak Z; Alexander PW; Chaplin JH; Keenan M; Charman SA; Perez CJ; Waterman MR; Chatelain E; Lepesheva GI
J Biol Chem; 2013 Nov; 288(44):31602-15. PubMed ID: 24047900
[TBL] [Abstract][Full Text] [Related]
5. Different Therapeutic Outcomes of Benznidazole and VNI Treatments in Different Genders in Mouse Experimental Models of Trypanosoma cruzi Infection.
Guedes-da-Silva FH; Batista DG; da Silva CF; Meuser MB; Simões-Silva MR; de Araújo JS; Ferreira CG; Moreira OC; Britto C; Lepesheva GI; Soeiro Mde N
Antimicrob Agents Chemother; 2015 Dec; 59(12):7564-70. PubMed ID: 26416857
[TBL] [Abstract][Full Text] [Related]
6. Novel structural CYP51 mutation in Trypanosoma cruzi associated with multidrug resistance to CYP51 inhibitors and reduced infectivity.
Franco CH; Warhurst DC; Bhattacharyya T; Au HYA; Le H; Giardini MA; Pascoalino BS; Torrecilhas AC; Romera LMD; Madeira RP; Schenkman S; Freitas-Junior LH; Chatelain E; Miles MA; Moraes CB
Int J Parasitol Drugs Drug Resist; 2020 Aug; 13():107-120. PubMed ID: 32688218
[TBL] [Abstract][Full Text] [Related]
7. Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi.
Hoekstra WJ; Hargrove TY; Wawrzak Z; da Gama Jaen Batista D; da Silva CF; Nefertiti AS; Rachakonda G; Schotzinger RJ; Villalta F; Soeiro Mde N; Lepesheva GI
Antimicrob Agents Chemother; 2016 Feb; 60(2):1058-66. PubMed ID: 26643331
[TBL] [Abstract][Full Text] [Related]
8. Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease.
Khare S; Liu X; Stinson M; Rivera I; Groessl T; Tuntland T; Yeh V; Wen B; Molteni V; Glynne R; Supek F
Antimicrob Agents Chemother; 2015 Oct; 59(10):6385-94. PubMed ID: 26239982
[TBL] [Abstract][Full Text] [Related]
9. Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development.
Moraes CB; Giardini MA; Kim H; Franco CH; Araujo-Junior AM; Schenkman S; Chatelain E; Freitas-Junior LH
Sci Rep; 2014 Apr; 4():4703. PubMed ID: 24736467
[TBL] [Abstract][Full Text] [Related]
10. Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease.
Riley J; Brand S; Voice M; Caballero I; Calvo D; Read KD
PLoS Negl Trop Dis; 2015 Sep; 9(9):e0004014. PubMed ID: 26394211
[TBL] [Abstract][Full Text] [Related]
11. Sterol 14α-Demethylase Structure-Based Optimization of Drug Candidates for Human Infections with the Protozoan Trypanosomatidae.
Friggeri L; Hargrove TY; Rachakonda G; Blobaum AL; Fisher P; de Oliveira GM; da Silva CF; Soeiro MNC; Nes WD; Lindsley CW; Villalta F; Guengerich FP; Lepesheva GI
J Med Chem; 2018 Dec; 61(23):10910-10921. PubMed ID: 30451500
[TBL] [Abstract][Full Text] [Related]
12. Listen to what the animals say: a systematic review and meta-analysis of sterol 14-demethylase inhibitor efficacy for in vivo models of Trypanosoma cruzi infection.
Bisio MMC; Jurado Medina LS; García-Bournissen F; Gulin JEN
Parasitol Res; 2024 Jun; 123(6):248. PubMed ID: 38904688
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for rational design of inhibitors targeting Trypanosoma cruzi sterol 14α-demethylase: two regions of the enzyme molecule potentiate its inhibition.
Friggeri L; Hargrove TY; Rachakonda G; Williams AD; Wawrzak Z; Di Santo R; De Vita D; Waterman MR; Tortorella S; Villalta F; Lepesheva GI
J Med Chem; 2014 Aug; 57(15):6704-17. PubMed ID: 25033013
[TBL] [Abstract][Full Text] [Related]
14. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts.
Molina J; Martins-Filho O; Brener Z; Romanha AJ; Loebenberg D; Urbina JA
Antimicrob Agents Chemother; 2000 Jan; 44(1):150-5. PubMed ID: 10602737
[TBL] [Abstract][Full Text] [Related]
15. Dialkylimidazole inhibitors of Trypanosoma cruzi sterol 14α-demethylase as anti-Chagas disease agents.
Suryadevara PK; Racherla KK; Olepu S; Norcross NR; Tatipaka HB; Arif JA; Planer JD; Lepesheva GI; Verlinde CL; Buckner FS; Gelb MH
Bioorg Med Chem Lett; 2013 Dec; 23(23):6492-9. PubMed ID: 24120539
[TBL] [Abstract][Full Text] [Related]
16. A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.
Doyle PS; Chen CK; Johnston JB; Hopkins SD; Leung SS; Jacobson MP; Engel JC; McKerrow JH; Podust LM
Antimicrob Agents Chemother; 2010 Jun; 54(6):2480-8. PubMed ID: 20385875
[TBL] [Abstract][Full Text] [Related]
17. Sterol 14α-Demethylase from Trypanosomatidae Parasites as a Promising Target for Designing New Antiparasitic Agents.
da Silva Santos-Júnior PF; Schmitt M; de Araújo-Júnior JX; da Silva-Júnior EF
Curr Top Med Chem; 2021; 21(21):1900-1921. PubMed ID: 33655860
[TBL] [Abstract][Full Text] [Related]
18. VFV as a New Effective CYP51 Structure-Derived Drug Candidate for Chagas Disease and Visceral Leishmaniasis.
Lepesheva GI; Hargrove TY; Rachakonda G; Wawrzak Z; Pomel S; Cojean S; Nde PN; Nes WD; Locuson CW; Calcutt MW; Waterman MR; Daniels JS; Loiseau PM; Villalta F
J Infect Dis; 2015 Nov; 212(9):1439-48. PubMed ID: 25883390
[TBL] [Abstract][Full Text] [Related]
19. Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51).
Lepesheva GI; Villalta F; Waterman MR
Adv Parasitol; 2011; 75():65-87. PubMed ID: 21820552
[TBL] [Abstract][Full Text] [Related]
20. Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.
Andriani G; Amata E; Beatty J; Clements Z; Coffey BJ; Courtemanche G; Devine W; Erath J; Juda CE; Wawrzak Z; Wood JT; Lepesheva GI; Rodriguez A; Pollastri MP
J Med Chem; 2013 Mar; 56(6):2556-67. PubMed ID: 23448316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
